poisar

Stocks · News reference

Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026

Benzinga Newsdesk

— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ALKS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth

    The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

    INDVALKSRDY
  3. Na

    Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

    Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.

    ALKSRGENPGEN